NONINVASIVE DIAGNOSIS OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C ON THE BASIS OF ROUTINE LABORATORY INDICES
- Authors: Malova E.S.1, Glazkova E.Y.1, Morozov V.G1, Melkonyan K.B1, Morozov A.V1, Safiullina N.H2, Balmasova I.P2
-
Affiliations:
- Hepatologist Medical Company
- A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
- Issue: No 1 (2013)
- Pages: 20-25
- Section: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/276411
- ID: 276411
Cite item
Open Access
Access granted
Abstract
Objective. To develop criteria for determining the stages of liver fibrosis while monitoring chronic hepatitis C (CHC) patients, by using the methods for noninvasive diagnosis of liver fibrosis on the basis of routine laboratory indices. Material and methods. Hemometry (COULTER AcT diff, USA) and biochemical blood analysis (Hitachi Roche — 902 Automatic analyzer, Japan) were made calculating the noninvasive diagnostic indices for fibrosis of the liver under its biopsy control, followed by the histological assessment of the biopsy samples according to the METAVIR scale. Results. Detection of the serum level of hyaluronic acid as a direct marker of fibrogenesis in patients with CHC is effective in recognizing liver cirrhosis (F4). Among the indirect methods for noninvasive diagnosis of liver fibrosis, there are APRI, Fibroindex, MDA, and GUCI, which show a high effectiveness in these patients with F3-F4 stages and among the combined methods for its noninvasive diagnosis, the Fibrometer, Hepascore, and Zeng tests are of diagnostic value virtually at all stages. Conclusion: The noninvasive diagnostic techniques based on routine laboratory indices need to be selectively assessed in patients with CHC, they feature varying diagnostic effectiveness at different fibrosis stages and may be recommended for this purpose during both primary examination of the patients and their monitoring in view of the established recommendations.
Full Text
About the authors
Elena S. Malova
Hepatologist Medical Company
Email: gepatolog@samtel.ru
Samara
E. Ya Glazkova
Hepatologist Medical Company
Email: gepatolog@samtel.ru
Samara
V. G Morozov
Hepatologist Medical Company
Email: gepatolog@samtel.ru
Samara
K. B Melkonyan
Hepatologist Medical Company
Email: gepatolog@samtel.ru
Samara
A. V Morozov
Hepatologist Medical Company
Email: gepatolog@samtel.ru
Samara
N. H Safiullina
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
Email: immunolab@mail.ru
I. P Balmasova
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
Email: immunolab@mail.ru
References
- Lang K., Weiner D.B. Immunotherapy for HCV infection: next steps. Expert Rev. Vaccines 2008; 7(7): 915-923.
- Gurtsevitch V.E. Human oncogenic viruses: hepatitis B and hepatitis C viruses and their role in hepatocarcinogenesis. Biochemistry (Moscow) 2008; 73(5): 504-513.
- Mysorekar V.V., Rao S.G., Mahadeva K.C. Liver histology in patients on hemodialysis with chronic hepatitis C viral infection. Indian J. Pathol. Microbiol. 2008; 51(2): 182-185.
- Yeshua H., Oren R. Non invasive assessment of liver fibrosis. Ann. Transplant. 2008; 13(2): 5-11.
- Larrousse M., Laguno M., Segarra M. et al. Noninvasive diagnosis of hepatic fibrosis in HIV/HCV-coinfected patients. J. Acquir. Immune Defic. Syndr. 2007; 46(3): 304-311.
- Stauber R.E., Lackner С. Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C. World J. Gastroenterol. 2007; 13(32): 4287-4294.
- Вельков В.В. (сост.) Сывороточные биомаркеры фиброза печени: до свидания, биопсия? М.: Lomonosoff Print, 2009. 40 с.
- Fontana R.J., Bonkovsky H.L., Naishadham D. et al. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin. Gastroenterol. Hepatol. 2009; 7(2): 219-226.
- Altman D.G., Bland J.M. Statistics Notes: Diagnostic tests 1: sensitivity and specificity. BMJ 1994; 308(6043): 1552.
- Ющук Н.Д., Знойко О.О., Сафиуллина Н.Х. и др. Диагностическая роль выявления коллагена IV типа и гиалуроновой кислоты в сыворотке крови больных хроническим гепатитом С для определения стадии фиброза печени. Тер. арх. 2005; 4: 50-55.
- Abdo A. A., Al Swat K., Azzam N. et al. Validation of three noninvasive laboratory variables to predict significant fibrosis and cirrhosis in patients with chronic hepatitis C in Saudi Arabia. Ann. Saudi Med. 2007; 27(2): 89-93.
- Wai C. T., Greenson J. K., Fontana R. J. et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38(2): 518-526.
- Dascalu D.N., Deac M. Non-invasive methods for hepatic fibrosis evaluation. Acta Medica Transilvanica 2010; 2(3): 244-246.
- Kim B.K., Kim do Y., Park J.Y. et al. М Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int. 2010; 30(4): 546-553.
- Vallet-Pichard A., Mallet V., Nalpas B. et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46(1): 32-36.
- Forns X., Ampurdanes S., Llovet J.M. et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36(4 Pt 1): 986-992.
- Zhou K., Gao C.F., Zhao Y.P. et al. Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 2010; 25(9): 1569-1577.
- Koda M., Matunaga Y., Kawakami M. et al. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007; 45(2): 297-306.
- Attallah A. M., Shina G.F., Omran M.M., Zalata K. R. A discriminant score based on four routine laboratory blood tests for accurate diagnosis of severe fibrosis and/ or liver cirrhosis in Egyptian patients with chronic hepatitis C. Hepatol. Res. 2006; 34(3): 163-169.
- Islam S., Antonsson L., Westin J., Lagging M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand. J. Gastroenterol. 2005; 40(7): 867-872.
- Testa R., Testa E., Giannini F. et al. Noninvasive ratio indexes to evaluate fibrosis staging in chronic hepatitis C: role of platelet count/spleen diameter ratio index. J. Intern. Med. 2006; 260(2): 142-150.
- Castéra L., Sebastiani G., Le Bail B. et al. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J. Hepatol. 2010; 52(2): 191-198.
- Kim S.U., Ahn S.H., Park J.Y. et al. Liver stiffness measurement in combination with noninvasive markers for the improved diagnosis of B-viral liver cirrhosis. J. Clin. Gastroenterol. 2009; 43(3): 267-271.
- Wu S.-D., Wang J.-Y., Li L. Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model: A comparative study. World J. Gastroenterol. 2010; 16(4): 501-507.
- Cales P., Oberti F., Michalak S. et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42(6): 1373-1381.
- Zhang Y.X., Wu W.J., Zhang Y.Z. et al. Noninvasive assessment of liver fibrosis with combined serum aminotransferase/platelet ratio index and hyaluronic acid in patients with chronic hepatitis B. World J. Gastroenterol. 2008; 14(46): 7117-7121.
Supplementary files
